Federal and state context, separated from access claims.
Information services
Services
Guides, comparisons, and research summaries for people following ibogaine in America—built to keep policy status, evidence quality, and safety context in view.
RESOURCE STATUS
Independent · evidence-firstResearch summaries that identify what remains uncertain.
Risk context without presenting treatment as approved.
Plain-language tools for families, advocates, and researchers.
Information built for careful comparison.
Open Field 30 organizes difficult questions into usable reference material. The aim is not to direct care, but to make it easier to distinguish research, regulation, safety signals, and unsupported certainty.
01 — RESEARCH SUMMARIES
Evidence snapshots
Structured summaries explain what a study examined, what it did not establish, and why investigational findings should not be confused with approved treatment. The clinical evidence map is designed for readers who want a clearer view of that distinction.
02 — POLICY TRACKING
Regulatory context
Federal and state developments are organized around the question they can actually answer: policy status, research activity, or access claims. The federal tracker keeps the national context visible without treating it as legal advice.
03 — DECISION FRAMEWORKS
Comparison guides
Plain-language guides help readers assess claims about settings, outcomes, and risk. A careful discussion of ibogaine success rates is most useful when definitions, timeframes, and study limits are stated plainly.
A practical reading workflow.
Use each resource as a checkpoint rather than a verdict: identify the claim, find its evidence type, check policy status, and keep safety context attached to every conclusion.
Claim type
Research finding
Specify population, endpoint, and study design.
Status check
Investigational
Separate research status from treatment approval.
Safety context
Required
Do not isolate benefit claims from known risks.
Language check
Uncertainty retained
Avoid promises, guarantees, and implied clinical advice.
“The useful question is not whether a claim sounds hopeful, but what kind of support it actually has.”
Our approach to evidence and independence explains how the resource frames uncertainty. For baseline U.S. regulatory context, the DEA’s drug scheduling overview describes how controlled-substance schedules are organized.
Guides & glossary
Terms, locations, and safety claims need context.
Our guides are designed to slow down search-driven conclusions. For example, information about ibogaine treatment locations may describe where services are advertised, but it does not establish U.S. approval, oversight, or suitability for any individual.
Likewise, a guide to long-term ibogaine side effects should be read as safety context rather than personal medical guidance. Ibogaine is associated with significant medical concerns, including cardiac risk, which is why evidence and safety discussions cannot be separated.
The FDA’s description of drug development and approval provides useful background for understanding why investigational interest is different from an approved indication.
What these resources do—and do not do.
Each guide is an information service. It can make a claim easier to inspect; it cannot determine medical appropriateness, legal compliance, or the quality of an individual provider.
Context for questions
Readers can compare research summaries, policy terminology, evidence limits, and safety language. A guide to ibogaine and PTSD treatment claims is framed around what is being asserted and what existing evidence can support.
No care recommendations
Open Field 30 does not diagnose, recommend treatment, assess an individual’s health, or validate a clinic. For a first orientation to the topic and tracker scope, return to the ibogaine policy and research tracker.
FAQ collection
Useful answers, with limits stated.
The goal is to clarify the category of question before offering a resource—not to replace medical or legal advice.
Does this resource provide treatment recommendations?
No. Open Field 30 is an independent information resource. It does not provide medical advice, treatment recommendations, or clinical services. First-person accounts such as an ibogaine trip report collection may be useful for understanding what is claimed, but they are not clinical evidence.
What does policy tracking cover?
Policy tracking distinguishes federal scheduling, state-level developments, research status, and claims about access or approval. The state policy map is intended as a starting point for that distinction, not legal advice.
How should readers approach comparisons outside the U.S.?
Location and cost comparisons need careful framing. For instance, a page on ibogaine clinics in Costa Rica may describe a separate setting, but it does not change U.S. regulatory status or establish safety, quality, or outcomes.
Open Field 30
Keep the evidence, policy, and risk in the same frame.
Use the tracker and its supporting guides to make sense of a fast-moving topic without turning uncertainty into a promise. This is independent public information, built for careful reading.